xtandi® is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (crpc). Dosage and administrationrndosing informationrnthe recommended dose of xtandi is 160 mg (four 40 mg capsules) administered orally once daily. Xtandi can be taken with...